Benefit of Whole Pelvic Radiotherapy Combined with Neoadjuvant Androgen Deprivation for the High-Risk Prostate Cancer

Table 1

Patient’s characteristics entered into prospective study for high-risk patients (𝑛=162).

Characteristic	WPRT + N-ADT (group A)	PORT (group B)	𝑃^∗
Patients (𝑛)	70 (100%)	92 (100%)	—
Mean age (years)	68.1 (range: 47–78)	67.9 (range: 48–79)	.81
Gleason score
2–7	34 (49%)	50 (55%)	.56
8–10	36 (51%)	42 (45%)
Clinical stage
T2c	20 (29%)	44 (48%)	.005
T3	50 (71%)	48 (52%)
Total dose	70.1 Gy	70.3 Gy	.22
PSA (ng/mL)
<30	25 (36%)	41 (44%)	.32
>30	45 (64%)	51 (56%)
%𝑁+
<30%	19 (27%)	38 (41%)	.088
>30%	51 (73%)	54 (59%)
Duration of L-ADT (months)	28.4	29.1	.13
Median followup (months)	54	55	.21

WPRT: whole pelvic radiotherapy, PORT: prostate radiotherapy only, PSA: prostate specific antigen, N-ADT: neoadjuvant androgen deprivation therapy, L-ADT: long-term adjuvant androgen deprivation therapy, %𝑁+: probability of metastases to pelvic lymph nodes calculated according to the Roach formula [18].
*Unpaired 𝑡-test for continuous variables; chi-square test for categorical variables.